Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

β-defensin 18 Inhibitors

β-defensin 18 inhibitors represent a specific group of compounds that interfere with the function of β-defensin 18, a member of the defensin family of small cationic peptides. β-defensins are typically associated with antimicrobial activities, and their structure is characterized by the presence of conserved cysteine residues that form intramolecular disulfide bridges. This structural feature provides β-defensin 18 with a highly stable, folded β-sheet structure, which is crucial for its interactions with cell membranes and other biomolecules. Inhibitors targeting β-defensin 18 typically work by disrupting these structural features or interfering with its binding sites, thereby modulating the peptide's interaction with its biological targets. The precise mechanism of inhibition can vary based on the chemical structure of the inhibitor, which might range from small molecules that bind competitively to synthetic peptides that mimic regions of the β-defensin molecule.

From a biochemical perspective, the inhibition of β-defensin 18 can alter key molecular pathways, as this peptide plays a role in several signaling cascades. These inhibitors may target specific molecular interactions that β-defensin 18 facilitates, such as its binding to cellular receptors or interaction with lipopolysaccharides on bacterial membranes. The development of β-defensin 18 inhibitors often involves studying the structural biology of the peptide, using techniques like X-ray crystallography or NMR spectroscopy to determine the critical sites for binding or function. Moreover, computational modeling can be employed to predict how potential inhibitors might interact with β-defensin 18, leading to structure-activity relationship (SAR) studies that refine the chemical characteristics required for potent inhibition. The design and synthesis of such inhibitors require careful attention to the balance between molecular stability, binding affinity, and specificity for β-defensin 18 over other defensins or peptides with similar structural motifs.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Dexamethasone

50-02-2sc-29059
sc-29059B
sc-29059A
100 mg
1 g
5 g
$91.00
$139.00
$374.00
36
(1)

Dexamethasone, a synthetic glucocorticoid, acts as an agonist for the glucocorticoid receptor, exerting anti-inflammatory effects by inhibiting the NF-κB pathway. This inhibition results in the downregulation of β-defensin 18, a critical antimicrobial peptide.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a potent and selective inhibitor of phosphoinositide 3-kinase (PI3K), disrupting the PI3K/Akt signaling pathway. By indirectly modulating downstream targets, LY294002 influences the expression of β-defensin 18, a key component of innate immunity.

BAY 11-7082

19542-67-7sc-200615B
sc-200615
sc-200615A
5 mg
10 mg
50 mg
$62.00
$85.00
$356.00
155
(1)

BAY 11-7082 inhibits IκBα phosphorylation, preventing NF-κB activation and subsequently reducing the transcription of β-defensin 18, an antimicrobial peptide involved in innate immune responses.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 acts as a selective inhibitor of p38 MAPK, disrupting the MAPK pathway and influencing the expression of β-defensin 18 through downstream signaling modulation.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is a potent and reversible inhibitor of c-Jun N-terminal kinase (JNK), affecting the JNK pathway and indirectly modulating β-defensin 18 expression by influencing the MAPK signaling cascade.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin, a fungal metabolite, is a potent and selective PI3K inhibitor, disrupting the PI3K/Akt pathway and indirectly impacting β-defensin 18 expression through downstream signaling.

BAY 11-7085

196309-76-9sc-202490
sc-202490A
10 mg
50 mg
$124.00
$526.00
55
(2)

Bay 11-7085 modulates the NF-κB pathway by inhibiting IκBα phosphorylation, leading to decreased β-defensin 18 expression, a crucial antimicrobial peptide associated with innate immunity.

NFκB Activation Inhibitor II, JSH-23

749886-87-1sc-222061
sc-222061C
sc-222061A
sc-222061B
5 mg
10 mg
50 mg
100 mg
$214.00
$257.00
$1775.00
$2003.00
34
(1)

JSH-23 is an inhibitor preventing nuclear translocation of NF-κB, specifically suppressing NF-κB-mediated β-defensin 18 transcription, a critical event in the regulation of innate immune responses.

PI-103

371935-74-9sc-203193
sc-203193A
1 mg
5 mg
$33.00
$131.00
3
(1)

PI-103 is a dual PI3K/mTOR inhibitor disrupting the PI3K/Akt pathway and indirectly modulating β-defensin 18 through downstream effects on the transcriptional machinery.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059, a selective MEK inhibitor, targets the MAPK pathway, influencing β-defensin 18 expression through downstream signaling modulation, a critical aspect in the regulation of innate immunity.